Chordia Therapeutics Receives Approval for Rare Disease Drug Designation for Rogoceki

TOKYO, Jul 28 (Pulse News Wire) – Chordia Therapeutics Inc. (190A.T) announced that the Pharmaceutical Affairs Council's Second Committee of the Ministry of Health, Labour and Welfare approved the designation of its lead pipeline drug, CLK inhibitor rogocekib, as a rare disease medicinal product for relapsed or refractory acute myeloid leukemia (AML).

Following formal procedures by the ministry, the company will promptly inform stakeholders upon receipt of the official notification. Rogocekib, developed under the code CTX-712, is a first-in-class selective oral small molecule inhibitor targeting CDC2-like kinases (CLK), which play a crucial role in cell proliferation. It has received orphan drug designation from the FDA for AML indications and is currently undergoing Phase 1/2 clinical trials in the United States.

Chordia Therapeutics, headquartered in Fujisawa, Kanagawa Prefecture, specializes in oncology-focused research and development. In addition to rogocekib, the company is also developing MALT1 inhibitor ocipumaltib (CTX-177), CDK12 inhibitor CTX-439, and GCN2 inhibitor among others. Details can be found on the company’s website.